The cyclin-dependent kinase Cdk5 controls multiple aspects of axon patterning in vivo  by Connell-Crowley, Lisa et al.
Brief Communication 599
The cyclin-dependent kinase Cdk5 controls multiple aspects of
axon patterning in vivo
Lisa Connell-Crowley, Maude Le Gall, Duc J. Vo and Edward Giniger
Cyclin-dependent kinase 5 (Cdk5) is one of a subfamily
of Cdks involved in the control of cell differentiation
and morphology rather than cell division. Specifically,
Cdk5 and its activating subunit, p35, have been
implicated in growth cone motility during axon
extension. Both Cdk5 and p35 are expressed in post-
mitotic neurons and are localized to growth cones [1–4].
The Cdk5–p35 complex interacts with the Rac GTPase, a
protein required for growth cone motility [5]. Studies
using cultured neurons have suggested that Cdk5
activity controls the efficiency of neurite extension [3,4].
Mutant mice lacking p35 exhibit subtle axon-guidance
defects [6], but these mice have severe defects in
neuronal migration [6–8], making it difficult to define
precisely the role of the Cdk5–p35 complex in vivo.
Here, we examined Cdk5 function in axon patterning in
the Drosophila embryo. Although our data support the
idea that Cdk5–p35 is involved in axonogenesis, they do
not support the view that Cdk5 simply promotes growth
cone motility. Instead, we found that disrupting Cdk5
function caused widespread errors in axon patterning.
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Results and discussion
Cdk5, like all Cdks, must associate with a regulatory
subunit to become active [9]. Thus, while Cdk5 is
expressed ubiquitously during development [10,11], the
spatial and temporal expression of its regulatory subunit
limits where and when Cdk5 can be active. We first exam-
ined whether a Cdk5 regulatory subunit is present at a
time and place consistent with a role in axon outgrowth in
the Drosophila embryo.
A fly Cdk5 regulatory subunit (Dp35; GenBank accession
number AF231134) was identified from the Drosophila
expressed sequence tag (EST) database using DNA
sequence of clones obtained by degenerate PCR followed
by cDNA and genomic library screens (Figure 1a and Sup-
plementary material). Dp35 encodes a ~52 kDa protein
with 31–40% overall identity to other p35 family
members, and 55–66% identity in its carboxy-terminal
half, where the Cdk5-binding and activation domains
reside [12]. Dp35 also has the amino-terminal myristoyla-
tion motif, which is conserved in p35 family members [13],
indicating that the cDNA is full length.
Figure 1
Dp35 binds and activates Cdk5. (a) Diagrammatic representation of
Dp35. The numbers indicate amino-acid positions. (b) GST pull-down
assay. Lanes 1 and 2, bacterially expressed GST–Dp35, or GST
alone; lanes 3 and 4, in vitro translated [35S]methionine-labeled Cdk5
or Cdk5K33A; lanes 5–8, Cdk5 or Cdk5K33A precipitated after
incubation with GST–Dp35 or GST beads. All molecular weights are
indicated in kDa. (c) Human 293T cells transiently expressing
UAS–Dp35–Myc or UAS–b -galactosidase (b -gal) and GAL4–VP16
were lysed and subjected to immunoprecipitation (IP) with anti-Myc
antibody. Samples were analyzed by western blotting using antibodies
to Myc, human Cdk5 (hCdk5), or human Cdk1 (hCdk1) and assayed
for histone H1 kinase activity. (d) Human 293T cells transiently
expressing GAL4–VP16 plus combinations of UAS–Dp35–Myc,
UAS–Cdk5–FLAG, UAS–Cdk5K33A–FLAG and UAS–b -galactosidase
were lysed, subjected to immunoprecipitation with anti-FLAG
antibodies, and kinase activity analyzed as in (c).
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We performed three tests, which together confirmed that
Dp35 and Cdk5 associate and cooperate functionally
in vitro and in vivo. First, we found that Dp35 binds Cdk5.
In an in vitro glutathione-S-transferase (GST) pull-down
assay, fly Cdk5 associated with GST–Dp35 but not with
GST alone, as did a mutant Cdk5 (Cdk5K33A) that is pre-
dicted to be kinase inactive (Figure 1b) [3]. Moreover,
Myc-epitope-tagged Dp35 (Dp35–Myc) expressed in
human 293T cells associated with endogenous human
Cdk5 in vivo, but not with Cdks 1, 2, 4 or 6 (Figure 1c and
Supplementary material). Second, we found that Dp35
activates Cdk5. Anti-Myc antibody immunoprecipitates
from human 293T cells containing Dp35–Myc and human
Cdk5 phosphorylated histone H1 (Figure 1c). Further-
more, anti-FLAG antibody immunoprecipitates from
human 293T cells containing fly FLAG-epitope-tagged
Cdk5 (Cdk5–FLAG) exhibited H1 kinase activity in the
presence, but not in the absence, of Dp35 (Figure 1d and
data not shown). In contrast, Cdk5K33A–FLAG was cat-
alytically inactive, although it did associate with Dp35
(Figure 1b,d and data not shown). Third, we found that
Dp35 interacts genetically with Cdk5 in the Drosophila
eye. Expression of one copy of Cdk5–FLAG in all cells of
the eye using the GMR–GAL4 driver had no effect on eye
surface morphology, whereas one copy of Dp35–Myc
caused a slight rough eye phenotype, presumably by acti-
vation of endogenous, low-level Cdk5 (Figure 2b,c). In
contrast, coexpression of Cdk5–FLAG with Dp35–Myc
severely disrupted eye morphology (Figure 2d). This syn-
thetic phenotype requires Cdk5 kinase activity because
coexpression with two copies of Cdk5K33A–FLAG sup-
pressed rather than enhanced the mild rough eye pheno-
type observed with two copies of Dp35–Myc
(Figure 2e–g). Thus, like their mammalian orthologs [3],
fly Cdk5 is activated by Dp35, whereas Cdk5K33A appears
to act as a dominant-negative mutant by titrating Dp35
and will be referred to below as Cdk5dn.
Next, we found that Dp35 is expressed in neurons at a
time and place consistent with a role in axon development
in vivo. Dp35 is expressed exclusively in the nervous
system, with strong expression in the brain, ventral nerve
cord and post-mitotic neurons of the peripheral nervous
600 Current Biology Vol 10 No 10
Figure 3
Dp35 is expressed in neurons and localizes to growth cones.
(a–c) In situ hybridization with a Dp35 probe. (a) Stage 17 embryo; b,
brain; vnc, ventral nerve cord. Expression was also observed in anterior
and posterior sensillae. Left, anterior; top, dorsal. (b) Lateral view of
lateral (l) and ventral¢ (v¢ ) clusters of sensory neurons in three abdominal
hemisegments. (c) CNS, stage 12.4 embryo. (d) Immunostaining of a
stage 12.4 embryo with antibody against horseradish peroxidase (HRP)
to reveal CNS neurons, neuroblasts and ganglion mother cells. Dp35
expression and HRP immunoreactivity were localized to the same
regions of the CNS, but Dp35 was restricted to the dorsal surface of
the CNS, where the first neurons are beginning to extend axons
(posterior commissure; the dark dot indicated by the arrow).
(e–g) Embryonic neurons expressing UAS–Dp35–Myc under the
control of 15J2–GAL4 and detected with anti-Myc antibodies. (e) A
dMP2 neuron, stage 12 CNS. (f) Chordotonal neurons, stage 16 PNS.
(g) dMP2 neurons from four hemisegments, stage 14 CNS.
Arrowheads, axons; arrow, dendrites; gc, growth cone.
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Figure 2
Cdk5 and Dp35 interact genetically. Scanning electron micrograph of
adult eyes expressing combinations of Cdk5, Cdk5K33A , and Dp35
with the eye-specific driver GMR–GAL4. (a) GMR–GAL4 alone.
(b) One copy of UAS–Dp35–Myc. (c) One copy of UAS–Cdk5–FLAG.
(d) One copy each of UAS–Dp35–Myc and UAS–Cdk5–FLAG. Note
the severe disorganization of eye morphology. (e) Two copies of
UAS–Dp35–Myc. Note the irregular rows of facets (arrow in the inset).
(f) Two copies of UAS–Cdk5K33A–FLAG. (g) Two copies each of
UAS–Dp35–Myc and UAS–Cdk5K33A–FLAG. The regular eye structure
here contrasts with the irregular morphology in (d,e).
(a) (b) (c) (d)
(e) (f) (g)
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system (PNS) (Figure 3a,b). The earliest Dp35 expression
was observed at stage 12 in clusters of cells in the central
nervous system (CNS) where the neurons that extend the
first CNS axons reside (Figure 3c,d). Dp35 expression was
not observed in neuroblasts, suggesting that fly
Dp35–Cdk5, like mammalian p35–Cdk5, is not involved
in cell division [2]. We examined the subcellular localiza-
tion of Dp35–Myc expressed in a small subset of neurons
using the 15J2–GAL4 driver. Consistent with the localiza-
tion of mammalian p35 [3,4], Dp35–Myc protein
expressed in CNS dMP2 neurons was present in the
neuron cell body and axon, including the growth cone
(Figure 3e,g). Dp35–Myc, expressed in PNS lateral chor-
dotonal neurons, was present in neuron cell bodies, den-
drites and axons (Figure 3f and data not shown).
Finally, we tested the functional consequences of altering
neuronal Cdk5 activity in vivo. We expressed Cdk5,
Cdk5dn and/or Dp35 in all post-mitotic neurons using the
elav–GAL4 driver, and then examined motor nerves
innervating lateral and dorsal body wall muscles of stage
16–17 embryos. 
Altering neuronal Cdk5 activity led to two important
observations. First, either increasing or decreasing Cdk5
activity produced errors in axon patterning. Second, there
was no simple correlation between Cdk5 activity and
axon/dendrite length. We activated endogenous neuronal
Cdk5 by expressing one copy of Dp35, which caused
subtle nerve defects in 32–40% of the embryos (Figure 4j).
The majority of defects occurred in the transverse nerve
(TN), with a few defects observed in segmental nerve a
(SNa) and the intersegmental nerve (ISN; see Supplemen-
tary material for distribution of defects). In contrast to
observations in cultured neurons [3,4], we found overex-
tended nerves, stalled nerves, and nerves with errors in
pathfinding and target recognition (Figure 4a–i). Two
copies of Dp35 increased the percentage of embryos with
defects (~61%; Figure 4j), suggesting that the effects of
Dp35 are dose dependent. The severity of the phenotype
was greatly enhanced by coexpressing Cdk5 with Dp35
(Figure 4k); 80% of the embryos exhibited nerve defects
that were more severe and widespread than when Dp35
alone was expressed (Figure 4a–i and see Supplementary
material). Nevertheless, the spectrum of phenotypes
observed (overextended, stalled and misrouted nerves) was
similar to that seen when Dp35 alone was expressed. 
We decreased neuronal Cdk5 activity by expressing
Cdk5dn [3]. One copy of Cdk5dn had no effect on axon
patterning, but two copies caused 32–35% of the embryos
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Figure 4
Altering Cdk5 function causes axon patterning defects. (a) Diagram of
an abdominal hemisegment depicting the three nerves examined in this
study. LBD, lateral bipolar dendritic neuron. (b–i) Peripheral motor
nerves of stage 17 (b,f) wild-type embryos, or embryos expressing
(c,d,g–i) Cdk5–FLAG with Dp35–Myc, or (e) Cdk5dn–FLAG alone,
visualized with anti-fasciclin 2 antibody. Arrowheads denote defective
nerves. (b) Wild-type SNa. (c) SNa lacking the dorsal branch.
(d,e) SNas with ectopic muscle contacts. (f) Wild-type dorsal
terminations of ISN and TN. (g) An overextended TN. (h) A stalled ISN.
(i) A misrouted TN that has extended towards the ISN in the next
segment. (j–m) Percentage of embryos exhibiting one or more nerve
defects when neuronal Cdk5 activity was altered by expression of the
indicated proteins. Control embryos expressed elav–GAL4 alone.
Letters in parentheses indicate independent UAS construct insertions
into the genome; each letter represents one insertion. Each bar
represents an average of two independent experiments; the results of
each experimental pair never differed by more than 14%, with an
average difference of less than 10%. For example, in four independent
trials with Cdk5dn, 31, 32, 33 and 33% of the embryos exhibited
defects. (n) Percentage of stalled, overextended, or misrouted nerves
in response to increased or decreased Cdk5 activity. Increased activity
includes defects seen with expression of Dp35 or Dp35 plus Cdk5;
decreased activity refers to defects seen with expression of Cdk5dn.
Expression of UAS–Cdk5, UAS–Cdk5dn, and UAS–Dp35 did not
alter neuron cell fate as assayed by staining with anti-eve antibody and
monoclonal antibody 22C10 (data not shown).
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to exhibit subtle nerve defects (Figure 4l and data not
shown). The majority of defects occurred in the TN, with
some defects in SNa and the ISN (see Supplementary
material). In addition, we observed a similar spectrum of
phenotypes as that seen with increased Cdk5 activity
(Figure 4n). With four copies of Cdk5dn, the percentage of
embryos with defects increased to 56%, indicating that the
effects of Cdk5dn, like those of Dp35, are dose dependent
(Figure 4j,l). Cdk5dn is likely to act, in part, by titrating
endogenous Dp35, because coexpression of two copies of
Cdk5dn with two copies of Dp35 suppressed the axonal
defects produced by two copies of Dp35 alone (31% versus
57%; Figure 4l). The phenotypic suppression observed with
Cdk5dn/Dp35 coexpression contrasts with the phenotypic
enhancement caused by Cdk5/Dp35 coexpression and indi-
cates that the Cdk5/Dp35-induced defects require kinase
activity. Additionally, the phenotypes of Cdk5 and Cdk5dn
appear to be mutually suppressive because, while the effects
of either Cdk5 or Cdk5dn are dose dependent, coexpression
of two copies of Cdk5 with two copies of Cdk5dn caused a
smaller percentage of embryos to exhibit defects than did
four copies of Cdk5dn (26% versus 56%; Figure 4m).
Our data confirm that Cdk5 is involved in axon develop-
ment in vivo, consistent with predictions of Cdk5 function
from studies using cultured neurons. Analysis of the phe-
notypes resulting from Cdk5/Dp35 expression in vivo
revealed, however, a different picture of Cdk5 function
than that observed in cultured neurons. Experiments using
cultured neurons suggested a simple correlation between
Cdk5 activity and the efficiency of neurite outgrowth [3,4].
In these experiments, it was not possible to examine axon
patterning, however. It is clear that Cdk5 and p35 are not
absolutely required for axon growth in vivo ([7,8] and data
not shown). Rather, we found that altering Cdk5 activity
degrades the accuracy of axon patterning: either increasing
or decreasing activity could promote or retard axon growth,
and cause errors in pathfinding and target recognition.
Perhaps the main function of Cdk5 is to ensure coordina-
tion of the many signaling pathways that are active in the
growth cone, akin to the ‘checkpoint’ function of cell-cycle
Cdks [14], and not simply to increase growth cone motility.
Such a ‘surveillance’ mechanism would be consistent with
the relatively subtle phenotypes observed when we modu-
late Cdk5 activity.
It is interesting that increasing or decreasing Cdk5 activity
both caused qualitatively similar nerve defects. This is rem-
iniscent of the effects produced when activity of the Rac
GTPase is increased or decreased [15]. As p35 interacts
with Rac [6], it will be of interest to determine whether the
axonal effects of Cdk5/Dp35 in vivo are mediated or regu-
lated by Rac. More generally, the ability to modulate Cdk5
activity in vivo will permit us to place Cdk5 genetically
within the signaling pathways that control growth cone
motility and guidance.
Supplementary material
Additional results and methodological details are available at
http://current-biology.com/supmat/supmatin.htm.
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